COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update

Summary

GlobalData's Medical Devices sector report, “COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update provides comprehensive information about the COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) are used to amplify and detect the specific nucleic acid sequences of SARS-CoV-2 virus at the point-of-care.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product’s current stage of development, territory and estimated launch date